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Abstract 
The major characteristic of COPD is systemic inflammation. This inflammatory process stimulates 
hematopoietic system, especially bone marrow, to release leukocytes and stimulates the liver to produce acute-
phase proteins such as fibrinogen. Fibrinogen levels tend to increase with severe airflow obstruction. High 
neutrophil levels are associated with a decrease in FEV1 even beyond exacerbations. In this study, we evaluated 
the relationship between fibrinogen and neutrophil levels with severity of COPD. The objective of this study 
was to analyze the correlation between fibrinogen and neutrophil levels with the incidence and severity of 
COPD. Design of this study was observational with a cross-sectional approach to population of COPD patients 
from May to July 2017 and healthy people as control. Consecutive sampling did a sampling of COPD patients. 
We evaluated clinical, CAT score, history of exacerbations, number of cigarettes consumed, fibrinogen, and 
neutrophil levels. From 35 COPD subjects and 21 healthy controls, we found that fibrinogen and neutrophils 
levels increased in COPD subjects compared to control (p <0.001), there was no significant correlation of 
fibrinogen and neutrophil levels with smoking status on COPD subjects (p> 0.05), Fibrinogen levels was 
significantly higher in exacerbation COPD than stable (p <0.001) but not with neutrophil, there was no 
significant correlation between smoking status and amount of cigarettes with  COPD severity(p> 0,05), there 
was significant correlation between fibrinogen levels with COPD severity (p <0.001) but not with neutrophils. 
Conclusion of this study is there was a correlation between fibrinogen with COPD incidence and severity.  
However, neutrophils levels associated with COPD incidence. 
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1. Introduction 
Currently, chronic obstructive pulmonary disease (COPD) is a global health problem. Global initiative for 
chronic Obstructive Lung Disease (GOLD) defineCOPDis a common, preventable and treatable disease that is 
characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar 
abnormalities usually caused by significant exposure to noxious particles or gases [1]. Pulmonary component is 
characterized by airflow obstruction that is not entirely reversible. Airflow obstruction is usually progressive 
and associated with pulmonary inflammatory responses to noxious particles or gases [2,3].  The chronic 
inflammatory response in COPD may induce parenchymal tissue destruction (caused emphysema), and disrupt 
normal repair and defense mechanisms (caused small airway fibrosis) [1]. This inflammatory process stimulates 
hematopoietic system especially bone marrow to release leukocytes and platelets and stimulates the liver to 
produce acute-phase proteins such as CRP and fibrinogen. Fibrinogen is a glycoprotein found in plasma, with a 
half-life about 100 hours and released in large quantities into circulation in response to stimulation of interleukin 
6 (IL-6) [4,5]. While neutrophils are a type of polymorphonuclear leukocytes, which have a role during the 
acute inflammatory phase, with a half-life in the circulation about 8 hours in humans [6]. One of fibrinogen 
degradation products is fibrinopeptide A and B which have a special proinflammatory effect as a neutrophil, 
monocytes, and macrophages chemoattractants [5].  In general, the inflammatory process increases with the 
severity of disease and persists despite quit smoking [7,8]. Fibrinogen levels tend to increase with severe airflow 
obstruction [9]. High neutrophil levels associated with decrease in FEV1 even beyond exacerbations [10,11] 
Neutrophil and fibrinogen levels are predictive markers for future exacerbations (Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints, ECLIPSE). Currently, fibrinogen considered as a 
prognostic biomarker in COPD patients [16,17].  In this study, we intend to explore the correlation between 
fibrinogen and neutrophil levels with incidence and COPD severity. Our hypothesis that fibrinogen and 
neutrophils levels associated with COPD severity. 
2. Methods 
Study Design 
This cross-sectional study was performed from May to July 2017. The flowchart showing the enrollment, 
screening, and outcome of this study was depicted in Figure 1. We enrolled outpatients and in patients 
diagnosed with COPD in Wahidin Sudirohusodo Hospital, and it‟s network. 
Subject 
We enrolled patients who were at least 40 years old diagnosed with COPD, which is stable and exacerbation 
stage with severity from mild to very severe. The diagnostic criteria were defined as an FEV1/FVC ratio <70%, 
determined when stable in accordance with the GOLD criteria. Excluded from the study were participants with 
a history of hypertension, stroke, Diabetes Mellitus, heart disease, autoimmune disease, asthma bronchial, 
pulmonary tuberculosis, chronic kidney disease, cancer, hematology disease, liver disease, and pregnancy. The 
subjects in the control group were non COPD healthy people who were older than 40 years with or without 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2019) Volume 48, No  1, pp 143-159 
145 
 
smoking history.All participants were informed about the nature and purpose of the study and gave their 
written consent. The study was approved by the Ethics Committee of Medical Faculty, Hasanuddin University, 
Makassar. 
Assesment 
Baseline demographic information, smoking history, medication history, and patient-reported history of 
exacerbations were collected. Exacerbations were defined according to the criteria of Anthonisen and his 
colleagues Patients who had deterioration in the symptoms of the respiratory tract that caused a change in 
medical treatment beyond normal daily variations were classified as “exacerbation COPD”. Patients who had 
not had any significant changes in their symptoms in the last 3 months and the ones who did not need 
additional inhaler treatment dosages or any other additional treatments were defined as “stable COPD”. At all 
visits, spirometry and symptom assessment using COPD Assesment Test, CAT and modified Medical Research 
Council,mMRC, were undertaken.  
The RBTand fibrinogen in blood was measured for both of group. After the collection of all databases, the 
differences among the parameters such as fibrinogen and neutrophil between the COPD group and those of the 
healthy group were compared. All the COPD patients received standard medication in accordance with the 
GOLD guidelines. Spirometry examination was performed on stable condition by using Spirovit Sp-1, Swiss-
made Schiller AG which has been calibrated first. Blood samples for fibrinogen examination inserted into a 
citrate tube (blue cap) containing the Na citrate buff, the tube inserted into the STA Compact tool by previously 
entering the patient data. Blood samples for neutrophil examination were inserted into a tube with EDTA 
potassium.  
Levels of hemoglobin, hematocrit, platelets, as well as white blood cells and types (neutrophils, lymphocytes, 
eosinophil, and monocytes),  were identified with automatic blood counters (Siemens Advia 2120, Diagnostic 
Solutions, Milan, Italy) with electrical impedance methods. All measurements will auto-exit from the tool. 
Statistical analysis 
The data obtained were analyzed with a computer using Statistical Package for Social Science (SPSS) version 
22. Statistical analysis was descriptive statistical analysis and Chi-Square, Fisher Exact, Mann-Whitney, 
Kruskal-Wallis and Kendall's tau-b statistic tests. Statistical test results are significant if the p-value of test 
<0.05. 
3. Result 
Our study recruited 56 subjects with age range 40 to 85 years, from 56 subjects we have 35 COPD subjects 
(62.5%) and 21 healthy subjects (37.5%) as controls with characteristics can be seen in following tables:  
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Table 1: Characteristics of Sex Distribution by COPD and Controls 
Sex 
Groups 
Total COPD Control 
 
male 
n 32 12 44 
% 91,4% 57,1% 78,6% 
female 
n 3 9 12 
% 8,6% 42,9% 21,4% 
Total 
n 35 21 56 
% 100,0% 100,0% 100,0% 
Fisher Exact test (p=0,005) 
Comparison of COPD group subjects between male and female was 91.4% and 8.6%, respectively, as well as 
with the control group, male greater than female in 57.1% and 42.9%. Distribution of sex differed significantly 
by group (p <0.01). The percentage of a male was higher in COPD than in controls (91.4% with 57.1%), 
whereas the percentage of females was higher in control than COPD (42.9% with 8.6%). 
Table 2: Characteristics of Age Distribution by COPD and Control Group 
Age 
Groups 
Total 
COPD Control 
 
<50 years 
N 2 14 16 
% 5,7% 66,7% 28,6% 
50-59 years 
N 5 5 10 
% 14,3% 23,8% 17,9% 
60-69 years 
N 18 2 20 
% 51,4% 9,5% 35,7% 
>=70 years 
N 10 0 10 
% 28,6% 0,0% 17,9% 
Total 
N 35 21 56 
% 100,0% 100,0% 100,0% 
Chi-Square test (p=0,000) 
In COPD group, subjects with age > 60 years were much more than age < 60 years (80% vs. 20%) while in the 
control group, subjects with age > 60 years were only two persons (9.5%). Age distribution was significantly 
different by group (p <0.001). Percentage of subjects with age < 60 years was higher in control than COPD, 
whereas the percentage of subjects with age > 60 years was higher in COPD than in controls.  
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Table 3: Characteristic of Body Mass Index Distribution by COPD and Control Group 
BMI 
Groups 
Total 
COPD Control 
 
Low BMI 
n 10 0 10 
% 28,6% 0,0% 17,9% 
Normal BMI 
n 17 21 38 
% 48,6% 100,0% 67,9% 
High BMI 
n 8 0 8 
% 22,9% 0,0% 14,3% 
Total 
n 35 21 56 
% 100,0% 100,0% 100,0% 
Chi-Square test (p=0,000) 
In the COPD group, the number of subjects with less BMI was ten people (28.6%), and high BMI were eight 
people (22.9%). While in the control group, all subjects had normal BMI (100%). The distribution of BMI 
differed significantly by group (p <0.001). Percentage of subjects with less nutrition and obese were higher in 
COPD than controls. 
In table 4,  all subjects of COPD and control groups were divided into smokers and nonsmokers. Seven 
subjects were nonsmokers, and 28 subjects were smokers in the COPD group while in the control group, 14 
subjects were nonsmokers and seven subjects were smokers. The percentage of subjects who smoked was 
significantly higher in COPD than in controls (80.0% and 33.3%) (p <0.001).  
Table 4: Characteristic of Smoking Status Distribution by COPD and Control Group 
Smoking Status 
Groups 
Total 
COPD Control 
 
Non-smokers 
n 7 14 21 
% 20,0% 66,7% 37,5% 
             Smokers 
n 28 7 35 
% 80,0% 33,3% 62,5% 
         Total 
n 35 21 56 
% 100,0% 100,0% 100,0% 
Chi Square test (p=0,000) 
Comparison of Fibrinogen and Neutrophil Levels between COPD Group and Control Group 
In Table 5 shows that fibrinogen levels were also significantly higher in COPD than in controls group (p 
<0.001), whereas fibrinogen levels in the COPD group compared with the control group (461.8 vs. 341.9) 
(p<0.001). The detailed results are displayed in the graph (Figure 2). While neutrophils levels were 
significantly higher in COPD than the control group (p <0.001), where neutrophil levels in the COPD group 
compared with the control group (66.5 vs. 51.0). The detailed results are displayed in the graph (Figure 3). 
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Table 5: Fibrinogen and Neutrophil Levels in COPD and Control Group 
Variable Groups N Median Mean SD p 
Fibrinogen 
COPD 35 415,0 461,8 126,4 
0,000 
Control 21 336,0 341,9 74,3 
Neutrophil 
COPD 35 67,9 66,5 13,1 
0,000 
Control 21 50,8 51,0 7,9 
      Mann-Whitney test 
 
Figure 2: Fibrinogen levels in COPD and Control Groups 
 
Figure 3: Neutrophils levels in COPD and Control Groups 
Correlation of Fibrinogen and Neutrophil Levels with Smoking Status in COPD Group  
Table 6: Correlation of Fibrinogen and Neutrophil Levels with Smoking Status  in COPD Group 
Variable Smoking Status N Median Mean SD p 
Fibrinogen 
Non-Smoker 7 386,0 393,0 105,4 
0,087 
Smoker 28 454,0 479,0 126,9 
Neutrophils 
Non-Smoker 7 65,5 62,8 14,1 
0,606 
Smoker 28 68,4 67,4 13,0 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2019) Volume 48, No  1, pp 143-159 
149 
 
Mann-Whitney test 
Table 6 shows that fibrinogen and neutrophil levels did not differ significantly according to smoking status (p> 
0.05). 
Correlation of fibrinogen and neutrophil levels with exacerbations in the COPD group  
Table 7 shows that Fibrinogen levels were significantly higher (median and mean) in COPD exacerbations 
than in stable COPD (p <0.001). 
Table 7: Correlation of Fibrinogen Levels with Exacerbation in COPD Group 
COPD N Median Mean SD p 
Stable 23 392,0 385,1 56,7 
0,000 
Exacerbation 12 597,0 608,9 83,8 
Mann-Whitney test 
While in table 8 showed that neutrophil levels did not differ significantly with exacerbations in COPD (p> 
0.05).  
Table 8: Correlation of Neutrophil Levels with Exacerbations in COPD Group 
COPD n Median Mean SD p 
Stable 23 67,600 65,026 13,8729 
0,362 
Exacerbation 12 72,900 69,308 11,5829 
Mann-Whitney test 
Correlation of Smoking Status with COPD Severity 
In Table 9.  shows that no significant difference in the distribution of smoking status with COPD severity (p> 
0.05). 
Table 9: Correlation of Smoking Status with COPD Severity 
Smoking Status 
COPD Severity 
Total 
Grade A/B Grade C/D 
 
Non Smokers 
n 2 5 7 
% 50,0% 16,1% 20,0% 
Smokers 
n 2 26 28 
% 50,0% 83,9% 80,0% 
Total 
n 4 31 35 
% 100,0% 100,0% 100,0% 
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Fisher Exact test (p=0,171) 
Table 10: Correlation of Cigarettes Distribution (Brinkman Index) with COPD Severity  in COPD  Smokers 
Group 
Cigarettes (IB) 
COPD Severity 
Total 
Grade A/B Grade C/D 
 
Light Smokers 
n 0 1 1 
% 0,0% 3,8% 3,6% 
Mild Smokers 
n 1 3 4 
% 50,0% 11,5% 14,3% 
Heavy Smokers 
n 1 22 23 
% 50,0% 84,6% 82,1% 
Total 
n 2 26 28 
% 100,0% 100,0% 100,0% 
Chi-Square test (p=0,321) 
Whereas in table 10.  shows that no significant difference in cigarettes distribution (Brinkman Index) with 
COPD severity in smokers COPD (p> 0.05). 
Correlation of Fibrinogen and Neutrophil Levels with COPD Severity 
In Table 11. shows that fibrinogen levels highest significantly on grade D and lowest on grade A (p <0.001). 
This suggests a significant correlation between fibrinogen levels and COPD severity. 
Table 11: Correlation of Fibrinogen and Neutrophil Levels with COPD Severity 
Variable COPD Severity n Median Mean SD p 
Fibrinogen 
Grade A 2 285,0 285,0 32,5 
0,000 
Grade B 2 297,0 297,0 12,7 
Grade C 19 396,0 407,8 43,1 
Grade D 12 597,0 604,2 91,9 
Neutrophil Grade A 2 55,3 55,3 26,9 
 
0,484 
Kruskal-Wallis test 
Figure 4 also shows that fibrinogen levels were going higher with increasing severity of COPD. 
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Figure 4: Correlation of Fibrinogen Levels with COPD Severity 
 
Figure 5: Correlation of Neutrophil Levels with COPD Severity 
While neutrophil levels did not differ significantly with COPD severity (p> 0.05). This shows that no significant 
correlation between neutrophils with COPD severity. The detailed results are displayed in the graph (Figure 5). 
4. Discussion 
In this study, our COPD group divided into smokers and nonsmokers. A number of smokers were 28 people, 
and non-smokers were seven people. Similarly, the control group divided into smokers and non-smokers, with a 
number of smokers were seven people and nonsmokers were 14 people. Percentage of subjects who smoked was 
significantly higher in COPD than in controls, 80.0% and 33.3% (p <0.001). Percentage of men was higher in 
COPD than in controls groups (91.4% with 57.1%) with percentage of subjects with age > 60 years higher in 
COPD than in control groups (80% with 9.5%). Based on BMI, percentage of subjects with less and high BMI 
was higher in COPD than in controls groups, 28.6%, and 22.9%, respectively.  Our ﬁndings are in agreement 
with recent studies by Garciario and his colleagues which found that compared with control group, COPD group 
were more men and smokers, with older age and a higher body mass index [26]. Similarly, in the ECLIPSE 
study, found that COPD patients are older than control and have more intense smoking than smokers with 
normal lung function [60].  
Comparison of Fibrinogen and Neutrophil Levels between COPD and Control Groups 
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Fibrinogen is a major plasma protein coagulation factor associated with adverse health effects when the levels 
are low or high. While COPD is a predictor of increased levels of fibrinogen [8]. In this study, fibrinogen levels 
were significantly higher in COPD than in controls groups (p <0.001), whereas fibrinogen levels in the COPD 
group compared with the control group (461.8 vs. 341.9). This finding is consistent with a shift in hemostatic 
balance that will activate coagulation in COPD. Various studies have demonstrated the prothrombotic 
conditions that occur in COPD [8,41]. Mona Fattouh and his colleagues also found a statistically significant 
increase of fibrinogen levels in COPD patients compared with the control group [4]. Neutrophils play an 
essential role in the pathogenesis of COPD and considered to be the primary effector cells involved in 
inflammatory process. In COPD, peripheral blood neutrophils activated by different inflammatory mediators 
then extravasation into lung tissue. Neutrophilia caused by neutrophil demarginations, slow neutrophil 
apoptosis, and bone marrow stimulation by growth factors [61,62]. In this study, neutrophil levels were 
significantly higher in COPD than in controls groups (66.5 vs. 51.0). Our ﬁndings are in agreement with recent 
studies by Erdal in and his colleagues which found that statistically, neutrophil levels were significantly higher 
in COPD than in control group. Several studies have shown that neutrophils are a key mediator of decreased 
lung function in COPD patients. When activated, neutrophils release several proteolytic enzymes, elastase and 
metalloproteinase matrices, which contribute to the formation of emphysema. Milara and his colleagues 
reported that peripheral blood neutrophils are constantly increasing in patients with COPD despite smoking 
cessation for many years. Increase the level of neutrophils associated with development of COPD. Increased 
levels of neutrophils in COPD patients are in line with previous studies and support the concept of systemic 
inflammation [36,55,62].  
Correlation of Fibrinogen and Neutrophil Levels with Smoking Status in COPD Group 
Long-term smokers can inhale more than 5,000 different compounds over several decades while slowly 
developing the pulmonary disease. In this study, we found that fibrinogen levels in smokers were higher than 
non-smokers in the COPD group (479,0 vs 393.0) but not statistically significant (p> 0.05). While neutrophil 
levels in smokers were higher than nonsmoker subject in COPD group (67,4 vs 62,8) but not statistically 
significant (p> 0,05). This is consistent with a study conducted by Agusti A. and his colleagues found that 
fibrinogen didn‟t affected by smoking activation, which in later studies concluded that IL-8 and TNF-α were 
strongly influenced by smoking while hs-CRP, IL-6 and fibrinogen were inflammatory biomarkers associated 
with COPD whereas WBC affected by both smoking and COPD [9]. YunitaArliny and his colleagues also 
found that there was no significant correlation between fibrinogen levels with smoking history and Brinkman 
Index [7].  Our results show elevated levels of fibrinogen and neutrophils in smokers COPD  versus non-
smokers although not statistically significant. Based on this study, we concluded that an increase of neutrophil 
level in COPD didn't only influence by smoking alone. Similarly, insignificant elevated fibrinogen levels in 
these patients are likely due to our COPD subjects still have comorbid factors such as hypertension and diabetes 
mellitus which unable to exclude It may also affect inflammatory biomarkers in COPD patients outside of 
smoking. Miller and his colleagues suggests that comorbid diseases such as heart disease, hypertension, and 
diabetes associated with increased systemic inflammation [63].  
Correlation of Fibrinogen and Neutrophil Levels with Exacerbations in COPD Group 
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Alteration in various systemic inflammatory indicators observed during COPD exacerbation, which 
accompanied by significant pulmonary function decline. The basic mechanism of COPD exacerbation episodes 
is "pulmonary inflammatory flareup," regardless of the "trigger" that causes it (infection, air pollution, etc.). 
Increased levels of airway inflammation during exacerbations are also accompanied by greater systemic 
inflammation, which has a role in higher cardiovascular morbidity. In our study, fibrinogen levels were 
significantly higher (median and mean) in exacerbations than in stable (p <0.001). Our ﬁndings are in agreement 
with recent studies by Kersul and his colleagues and Fattouh and his colleagues who found that during COPD 
exacerbations, plasma fibrinogen levels were elevated compared with stable phases or smokers control subjects 
[4, 57].  Several studies have shown that peripheral blood neutrophils are increasing during exacerbations [64]. 
Peripheral blood neutrophils increased during exacerbations, with levels correlated with exacerbations severity. 
The percentage of blood neutrophil apoptosis in COPD exacerbations decreases. In our study, we found that 
levels of neutrophils in stable COPD (65.026) increases during exacerbations (69.308), but this result was not 
statistically significant (p> 0.05). An acute exacerbation can be caused by various causes including infection 
(bacteria or virus), bronchospasm, air pollution, or sedative class drugs [22]. While an increase in neutrophils 
itself only dominated by more severe exacerbations caused by bacterial infections [65]. In addition, in some 
exacerbated subjects, we did not immediately take blood samples on the same day our subject admitted to the 
hospital. At the time we took blood samples, the subjects had already received antibiotic therapy. This may 
affect levels of neutrophils in COPD subjects. Neutrophils are not acute-phase reactions, short-lived cells with a 
half-life in circulation about 8 hours in humans, compared with fibrinogen that has a half-life about 100 hours 
[5,6]. The nature of neutrophil, which is faster vanish in circulation, affect the neutrophil levels in our study. 
Correlation of Smoking Status with COPD Severity 
In our study, we found that no significant difference in smoking status distribution with COPD severity (p> 
0.05) and no significant difference in cigarettes distribution (Brinkman Index) with COPD severity in smokers 
COPD (p> 0, 05). Our ﬁndings are in agreement with recent studies by Agusti A. and his colleagues in 
ECLIPSE, found that the number of cigarettes which consumed almost the same at different stages of GOLD. 
Smoking is a major risk factor for COPD, but it has been suggested that not all smokers develop into this disease 
because of the presence the vulnerable and non-vulnerable smokers. Various 'levels of vulnerability' have been 
proposed by Fletcher and Peto in 1977, and have recently been confirmed in the Framingham Offspring Cohort, 
which there is a potential difference or genetic interaction with other risk factors, such as nutrition or infection 
[60].  
Correlation of Fibrinogen and Neutrophil Levels with COPD Severity 
Our study showed that the highest fibrinogen levels were in grade D and the lowest levels were in grade A (p 
<0.001). This suggests a significant relationship between fibrinogen levels and COPD severity. Our ﬁndings are 
in agreement with recent studies by Cockayne and his colleagues found that fibrinogen increases with COPD 
severity, consistent with its role as a chronic inflammatory marker [66]. Several mechanisms proposed as the 
origin of increased systemic inflammation in COPD. First, inflammatory mediator 'spillover' from the lung 
compartment; Second, inflammatory reaction due to tissue hypoxia, and third, the reaction caused by the 
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proinflammatory product of bacterial lipopolysaccharide [65].  In our study, neutrophil levels were higher in line 
with COPD severity, where the lowest score (55.3) was found in grade A while the highest score (70.6) was 
found in grade D but not statistically significant (p> 0.05 ). It shows no significant correlation between blood 
neutrophils and COPD severity. Our ﬁndings are in agreement with recent studies by Z He and his colleagues 
found that in peripheral blood analysis showed no significant difference between groups of COPD subjects 
based on GOLD criteria with the proportion of white blood cells or neutrophils [67].  Xiong and his colleagues 
and Lee and his colleagues found that neutrophils did not correlate with severity of respiratory tract obstruction 
and death in COPD [55, 65]. Based on these studies, it concluded that Neutrophil to Lymphocytes Ratio reflects 
severity and activity of COPD better than neutrophilia or lymphopenia alone where this ratio integrates 
neutrophilia as an indicator of inflammation and lymphopenia as an indicator of overall immune deficiency 
found in COPD [65]. Insignificant increase neutrophil levels with COPD severity in our study is likely due to 
blood sampling was done by random, not specified at any one time. Circadian variation of neutrophil in 
circulation has been reported, with neutrophil levels being highest in the blood during the day [68]. Also, in this 
study, we do not exclude any subject who use antibiotics that can affect neutrophils levels.  
Limitations 
Several potential limitations of this study are worth discussing. First, our COPD subject still accompanied by a 
comorbid disease which included exclusion criteria, this may lead to confusion in the results of the study. 
Several studies have suggested that this disorder is more common in COPD patients and, therefore, may 
contribute to its proinflammatory state. Secondly, COPD subjects in our study, 28% used inhaled and systemic 
corticosteroids. This can lead to underestimation of systemic biomarker levels. However, the effect of inhaled 
corticosteroids on inflammatory biomarkers remains controversial. Thirdly, the number of samples in our study 
is small so that it could not generalize some findings. 
5. Conclusion 
There is a significant correlation between increased levels of fibrinogen with the incidence and severity of 
COPD. In addition, there is a significant correlation between elevated levels of neutrophils with COPD 
incidence 
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